(Photo Courtesy: www.bedsty.com)
The grant is on a worldwide basis, excluding the countries of Asia (other than Japan) and Africa.
Salix is required to make an up-front payment and, upon achievement, additional regulatory milestone payments to Cipla in respect of the new license agreement regarding the ‘Rifaximin Complexes' patent rights.
Salix also will pay a royalty on net sales of products covered by the ‘Rifaximin Complexes' patents licensed to Salix.
Last year, Cipla announced the expansion of its existing collaboration with MEDA by granting global commercialization rights for a proprietary combination nasal spray product (fluticasone and azelastine), Dymista.